The FDA granted a new indication for upadacitinib (Rinvoq, AbbVie) 15 mg once daily, for the treatment of adults with active ankylosing spondylitis (AS) who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers.
The FDA approval for AS is supported by efficacy and safety data from the phase 3 SELECT-AXIS 2 clinical trial evaluating upadacitinib in patients who had an inadequate response or intolerance to one or two biologic disease-modifying